Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Compounds for the treatment of metabolic disorders

This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related dis-eases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 dia-betes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslip-idemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of can-cer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

Safe chemical uncouplers for the treatment of obesity

The present invention relates to the use of at least one compound with inhibitory activity on kynurenine 3-hydroxylase for the preparation of a medicament for the prevention and/or treatment of diabetes.

Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes

Compound for the treatment of metabolic disorders

The present invention relates to a pharmaceutical composition comprising, as active principles, metformin, optionally in the form of one of its pharmaceutically acceptable salts, and a 4-oxobutanoic acid, in combination with one or more pharmaceutically acceptable excipients. These compositions are particularly suitable for treating non-insulin-dependent diabetes.

Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes

The invention concerns a pharmaceutical composition containing, as active principle, a compound of formula (a) in which groups A and B are selected independently of each other among: a mono-cyclic, bi-cyclic or tri-cyclic aryl group having 6 to 14 carbon atoms; a heteroaraomatic group selected among the pyridyl, pyrimidyl, pyrrolyl, furyl and thienyl groups; an alkyl group having 1 to 14 carbon atoms; a cycloalkyl group having 5 to 8 carbon atoms; a saturated heterocyclic group selected among the tetrahydrofuryl, tetrahydropyrranyl, piperidinyl and pyrrolidinyl groups; its solvate or a salt of this acid with a pharmaceutically acceptable base.

Pharmaceutical composition containing 4-oxo-butynic acids

The present invention relates to the use of a 4-oxobutanoic acid derivative for the preparation of a pharmaceutical composition for treating inflammation.

Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

La presente invention concerne une composition pharmaceutique comprenant, a titre de principe actif, un compose de formule (I) dans laquelle les groupes A et B sont choisis independamment l'un de l'autre parmi: un groupe aryle mono-, bi- ou tricyclique ayant de 6 a 14 atomes de carbone; un groupe heteroaromatique choisi parmi les groupes pyridyle, pyrimidyle, pyrrolyle, furyle et thienyle; un groupe alcoyle ayant de 1 a 14 atomes de carbone; un groupe cycloalcoyle ayant de 5 a 8 atomes de carbone; un groupe heterocyclique sature choisi parmi les groupes tetrahydrofuryle, tetrahydropyrranyle, piperidinyle et pyrrolidinyle; son solvate ou un sel de cet acide avec une base pharmaceutiquement acceptable.

Maizeray Philippe

Papers

Pharmaceutical composition containing 4-oxo-butynic acids

Use of 4-oxobutanoic acid derivatives in the treatment of inflammation

Compositions pharmaceutiques contenant des acides 4-oxo-butanoiques

Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation